Janssen and Protagonist to Develop, Market PTG-200 for the Treatment of IBD

Janssen and Protagonist to Develop, Market PTG-200 for the Treatment of IBD
Janssen Biotech and Protagonist Therapeutics are partnering to develop, manufacture, and market PTG-200 as a treatment for Crohn’s disease and ulcerative colitis (UC). PTG-200 is a potential first-in-class oral IL-23R antagonist under development for moderate to severe Crohn’s disease, a form of inflammatory bowel disease (IBD). The drug has received investigational new drug (IND) status by

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *